Axsome projects AUVELITY peak revenue of at least $8B as AXS-12 nears May 1, 2027 PDUFA

What happened: Axsome Therapeutics reported Q3 2026 results and projected peak revenue of at least $8B for AUVELITY, with AXS-12 approaching a May 1, 2027 PDUFA date. Key numbers: Total revenue of $260 million in the quarter; AUVELITY peak revenue projected at least $8B; AXS-12 PDUFA date May 1, 2027. Why it matters: Management cited continued commercial progress and pipeline advancement as drivers of the quarter, and the AUVELITY peak projection frames the commercial scale it expects from the franchise.

Axsome Therapeutics reported Q3 2026 results and projected peak revenue of at least $8B for AUVELITY, with AXS-12 approaching a May 1, 2027 PDUFA date.

Management cited continued commercial progress and pipeline advancement as drivers of the quarter, and the AUVELITY peak projection frames the commercial scale it expects from the franchise.